Latest news

Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer

 Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer

Seasoned CEO with 30 years’ experience in the healthcare industry

Edinburgh, United Kingdom – 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company, today announces the appointment of Dr Bernhard Sixt as Chief Executive Officer, effective immediately.

Dr Sixt has 30 years of healthcare industry experience in the development and commercialisation of laboratory services, in vivo and in vitro diagnostics, and pharmaceuticals for industry leaders such as Amersham (now part of GE Healthcare) and Nycomed Pharma (now part of Takeda).  Since leaving Amersham, Bernhard has led several companies. He is a co‑founder of Agendia and served as its CEO from 2003 until 2011 and in 2005 founded Ipotuba, a pioneer for addressing the emerging need for pharmaceutical cryo-logistics. He also led ImmunID, an innovator in precision immuno-oncology, from 2013 until 2016.  Dr Sixt holds a Master of Science degree in Biochemistry and Chemistry from Ludwig Maximilians University (LMU) and a PhD from the Technical University (TU), both in Munich, Germany.

Roy Davis, Chairman of the Board of EM Imaging, said: “We are very pleased to have attracted someone of Bernhard’s calibre and I warmly welcome him to EM Imaging. Bernhard’s proven track record and experience in leading and growing companies will be invaluable in taking EM Imaging on its next stage of development.

“The board would also like to thank Ian Wilson, a former Amersham colleague of Bernhard, for his contribution in building and leading EM Imaging to its current stage.”

Bernhard Sixt, Chief Executive Officer of EM Imaging, commented: “Throughout my industry career I have always been excited by the potential that optical imaging modality offers.  I am very pleased to join EM Imaging which has the opportunity to maximise the potential offered by advanced optical imaging.  Our lead product, EMI-137, offers a “real time in situ pathology vision” to physicians and surgeons and has the potential for improved cancer detection. It has been safely administered to 69 patients so far demonstrating encouraging data and in a phase 1/2a colonoscopy study demonstrated a 17% increase in cancer lesion detection compared to standard colonoscopy, and increased detection of high risk lesions.  Currently EMI-137 is also being trialled in several other cancer indications.”

ENDS

 

Further information: 

Edinburgh Molecular Imaging

Bernhard Sixt, CEO:

media@emimaging.com

Tel: +131 (0) 658 5308

@edinimage #CRCcure 

Optimum Strategic Communications

Mary Clark, Supriya Mathur

Tel: +44 (0) 203 950 9144

healthcare@optimumcomms.com 

Notes for Editors: 

About Edinburgh Molecular Imaging

EM Imaging’s highly novel molecular imaging technology platform targets disease detection in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.  With a portfolio focused on development and commercialisation, the company’s optical imaging agents see disease in the body in real time, and help clinicians make time-critical diagnostic and treatment decisions.

EM Imaging’s “SMART” optical agents visualise pathology in vivo by lighting up cells, enzymes and receptors present in disease, reducing the time to diagnose patients from days to seconds, enabling point of care treatment selection and early intervention.  For more information, please visit www.emimaging.com.

The company was formed in 2014 by lead investor Epidarex Capital, a venture capital firm specialising in early stage life science investments.  For more information, please visit www.epidarex.com.

About Optical imaging

Optical imaging is a technique for non-invasively looking inside the body, as is done, for example, with x-rays.  Unlike x-rays, which use ionizing radiation, optical imaging uses visible light and the special properties of photons to obtain detailed images of organs and tissues as well as smaller structures including cells.

adminEdinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer
read more

Edinburgh Molecular Imaging Ltd Appoints New Chairman

EDINBURGH, Scotland, October 29, 2018

Roy Davis appointed as Non-Executive Chairman

– Current Chair John Jeans to continue as Non-Executive Director

Edinburgh Molecular Imaging Ltd (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces the appointment of Roy Davis as non-executive Chairman with immediate effect. John Jeans, who has served as non-executive Chairman since August 2015, will remain on the Board of EM Imaging as a non-executive director.

Mr Davis is currently Chairman of Medica Group plc (the UK’s leading tele-radiology company). He was formerly CEO of Optos Plc, a leading retinal imaging manufacturer from 2008 to 2015 until its sale to Nikon for $400 million in 2014; he continues to be an advisor to Nikon. Prior to this, Mr Davis was CEO of Gyrus Group plc, a leading medical device company focused on minimally invasive surgery and visualisation until it was acquired by Olympus in 2008 for approximately $2 billion.

Mr Davis has over 30 years of operational expertise and strategic consulting experience and holds a mechanical engineering degree, with honours, from Southampton University and an MBA from the London Business School.

Commenting on the appointment, John Jeans said:

I am delighted to welcome Roy to the Board. Given his extensive experience in healthcare and diagnostics, he is a very valuable addition to the Company. Additionally, his leadership skills and deep expertise in medical technology will be central to EM Imaging in bringing its highly novel optical imaging technology to the forefront of the global molecular imaging market. I am pleased to continue to stay on as Director and support Roy, the management team and Board at this exciting stage of the companys growth.

Roy Davis, incoming Non-Executive Chairman of EM Imaging Ltd., said:

The team at EM Imaging has made great progress in establishing a strong portfolio of optical imaging opportunities. I am excited to have this opportunity to contribute to the next phase of the Companys development.

Liz Roper, Partner Epidarex Capital and Board Director, EM Imaging Ltd., said:

We are very pleased to have Roy join as Chair of the Board of EM Imaging, bringing his significant expertise and leadership at a pivotal time in the Companys development . We would like thank John for his significant contribution to the early growth and success of EM Imaging and look forward to working with both Roy and John in continuing to build a leading company in next-generation, optical imaging.

About Edinburgh Molecular Imaging
EM Imaging’s highly novel molecular imaging technology platform targets disease detection in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue. With a portfolio focused on development and commercialisation, the company’s optical imaging agents see disease in the body in real time, and help clinicians make time-critical diagnostic and treatment decisions.
EM Imaging’s “SMART” optical agents visualise pathology in vivo by lighting up cells, enzymes and receptors present in disease, reducing the time to diagnose patients from days to seconds, enabling point of care treatment selection and early intervention. For more information, please visit www.emimaging.com.
The company was formed in 2014 by lead investor Epidarex Capital, a venture capital firm specialising in early stage, life science investments. For more information, please visit www.epidarex.com.

About Optical imaging
Optical imaging is a technique for non-invasively looking inside the body, as is done, for example, with x-rays. Unlike x-rays, which use ionizing radiation, optical imaging uses visible light and the special properties of photons to obtain detailed images of organs and tissues as well as smaller structures including cells.

Further information:

Edinburgh Molecular Imaging
Barry Knight, CFO
Email: media@edinimage.com
Tel: +131-(0)-658-5308 / +44-(0)-7967-588463
@edinimage #CRCcure

adminEdinburgh Molecular Imaging Ltd Appoints New Chairman
read more

EDINBURGH MOLECULAR IMAGING ANNOUNCE BOWEL CANCER UK AND BEATING BOWEL CANCER AS CHARITY PARTNER

Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner.

EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer to raise funds for the charity and increase awareness of Scotland’s second biggest cancer killer. The clinical phase biotechnology company focuses on enabling image guided therapy.

The company’s molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.

Emma McGeever, Scotland Fundraising Manager at Bowel Cancer UK and Beating Bowel Cancer, said: “We are absolutely delighted to be chosen as EM Imaging’s Charity partner. Bowel cancer is Scotland’s third most common cancer and without the amazing support from organisations like EM Imaging we couldn’t continue to fund the highest quality research and essential information and support services that will save lives from bowel cancer.”

John Jeans, Chairman of the Board at EM Imaging Ltd., said: “It is with great pleasure that EM Imaging will be working with Bowel Cancer UK and Beating Bowel Cancer to help raise funds for, and awareness of, this devastating disease. We are already looking forward to our first fund raising events this year with EM Imaging employees participating in #RowAMarathon in June and the Edinburgh Half Marathon. EM Imaging’s mission to help improve patient outcomes in bowel cancer can only be helped by working with such inspiring partners.”

ENDS

For more information and interviews contact Emily.Stallard@bowelcanceruk.org.uk or call 0207 940 1760 / 0755 312 1454

Follow us on social media: Twitter Bowel Cancer UK / Beating Bowel Cancer and Facebook charityBCUK / BeatingBC

Notes to editors

 

About Bowel Cancer UK and Beating Bowel Cancer
Bowel Cancer UK and Beating Bowel Cancer is the UK’s leading bowel cancer charity. We are determined to save lives, improve the quality of life and support all those affected by bowel cancer. We enable and fund research, provide information and support to patients and their families, educate the public and professionals about the disease and campaign for early diagnosis and best treatment and care for all.


About bowel cancer

Bowel cancer is the fourth most common cancer in the UK and the second biggest cancer killer, affecting both men and women. Every 15 minutes in the UK someone is diagnosed with bowel cancer. That’s almost 42,000 people every year.

Bowel cancer is treatable and curable especially if diagnosed early. Nearly everyone diagnosed at the earliest stage will survive bowel cancer. However, this drops significantly as the disease develops. Early diagnosis really does save lives.

 

The symptoms of bowel cancer can include:

  • Bleeding from your bottom and/or blood in your poo
  • A persistent and unexplained change in bowel habit
  • Unexplained weight loss
  • Extreme tiredness for no obvious reason
  • A pain or lump in your tummy

 

Most people with these symptoms don’t have bowel cancer. Other health problems can cause similar symptoms. If you have one or more of these, or if things just don’t feel right, see your GP.

  • Extreme tiredness for no obvious reason
  • Unexplained weight loss
  • A pain or lump in your tummy

 

Most people with these symptoms don’t have bowel cancer. Other health problems can cause similar symptoms. But if you have one or more of these, or if things just don’t feel right, go to see your GP.

adminEDINBURGH MOLECULAR IMAGING ANNOUNCE BOWEL CANCER UK AND BEATING BOWEL CANCER AS CHARITY PARTNER
read more

Edinburgh Molecular Imaging Commences Phase II European Cancer Trial

Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer

Edinburgh, UK – 19 September 2017: Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a pivotal Phase IIb clinical trial with its novel compound, EMI-137, in patients with high suspicion of colorectal cancer (CRC).  EM Imaging is backed by Epidarex Capital together with Scottish Investment Bank and Wren Capital.

Colorectal cancer is the third most common cancer worldwide with approx. 41,000 people diagnosed every year in the UK and over 1.4 million people worldwide. Imaging with white light colonoscopy is the established method for the diagnosis and prevention of CRC. However, up to a quarter of cancerous and precancerous bowel cancer tumours can be missed using this method.

EMI has developed a novel fluorescent Optical Imaging Agent – EMI-137 – which targets and “lights-up” the cancer cells, helping surgeons to more easily identify and remove suspicious tumours.  EMI-137 targets the cancer marker C-Met, which is overexpressed in CRC cells and cancer precursor cells.

The phase IIb study will be conducted by the Centre for Human Drug Research (CHDR), a world renowned clinical research organization based in Leiden, in close collaboration with the Leiden University Medical Centre and the University Medical Center of Gröningen, The Netherlands.  The Clinical Investigators at these sites are Professor James Hardwick and Dr Wouter Nagengest, who are among Europe’s leading clinicians advancing the diagnosis and treatment of colorectal cancer.

Ian Wilson, CEO of Edinburgh Molecular Imaging, commented:

“The identification of flat, small non-polypoid lesions is a major problem as they cannot be detected by conventional imaging. EMI-137 has the potential to address this major unmet medical need by combining targeted molecular imaging probes and advanced imaging technology to improve polyp detection.  Our team is extremely motivated to complete this product’s development and get it into the hands of physicians in order to benefit patients.”

Deborah Alsina, MBE, Chief Executive of Bowel Cancer UK, added:

“More than 9 out of 10 people will survive bowel cancer if it is detected at an early stage when treatments are more likely to be effective.  Optical imaging techniques, using agents like EMI-137, could potentially reduce the number of polyps missed during colonoscopy, therefore significantly improving outcomes for patients. This next phase of the research will help us understand whether this method could be introduced routinely in practice and offer real benefits to patients. It is vital that that the UK and Europe continue to invest in studies and clinical trials to keep finding quicker and more effective ways to identify and diagnose patients early when the disease is curable.”

The objective of the clinical study is to assess the efficacy of EMI-137 in aiding clinicians to detect pathological lesions during colonoscopy. The study will involve up to 200 patients with a high suspicion of CRC.  Interim results from the trial are expected in Q1 2018. EM Imaging and CHDR collaborated on the Phase I study of EMI-137 which showed a 25% increase in bowel cancer lesion detection compared to standard colonoscopy.

Improved polyp detection in this study might lead to further studies in extended target populations and, possibly, in the end to a wider adoption of fluorescence-guided endoscopy.

EM Imaging is also working with doctors and clinical centres in the UK, Europe, US and Asia to use EMI-137 to detect tumours during surgery. Studies are planned to look at improving cancer detection in a range of cancers including Breast Cancer, Gastric Cancer, Thyroid Cancer, Head & Neck Cancer, Prostate Cancer and Brain Cancer.

ENDS

Further information:

Edinburgh Molecular Imaging

Ian Wilson
Tel: +44 131 658 5307
Email: media@emimaging.com
@edinimage  #CRCcure

Centre for Human Drug Research
Josine Vrouwe, MD
Email: jvrouwe@chdr.nl
Tel:  +31 71 751 7163
For patients: www.proefpersoon.nl

About Edinburgh Molecular Imaging

Edinburgh Molecular Imaging (EM Imaging) is a clinical phase biotechnology company focused on enabling image-guided therapy. The Company’s molecular imaging technology, based on Fluorescent Imaging, has the potential to detect disease in real-time during interventional procedures including surgery, providing more accurate treatment while sparing healthy tissue.

EM Imaging discovers and develops small molecules and peptides that, when conjugated with fluorescent dyes, targets diseased tissue – specifically cancerous cells. This will provide the clinician with a clearer view and decision-making tool to benefit the patient.  For more information go to: www.emimaging.com

About Centre for Human Drug Research

The Centre for Human Drug Research (CHDR) is a world renown Clinical Research Organisation in Leiden, The Netherlands with strong academic links which focuses on early drug development. Its mission is to develop compounds, therapeutic or diagnostic in an innovative and highly informative manner to allow early introduction of novel treatment paradigms into the clinic.  ww.chdr.nl

About Epidarex Capital

Epidarex invests in early-stage, high growth life science and health technology companies in under-ventured markets in the US and Europe.  With offices in Bethesda, Maryland and in Edinburgh, Scotland, Epidarex works closely with the management of its portfolio companies to more effectively translate their world-class research to commercial, patient-driven success.

Epidarex’s international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. Its global network includes investment professionals, scientists, industry executives, health practitioners, policy experts, regulatory advisors and business development leaders.  More information is available at www.epidarex.com

References

http://www.cancerresearchuk.org/about-cancer/type/bowel-cancer/about/risks/high-risk-groups-for-bowel-cancer

 

 

adminEdinburgh Molecular Imaging Commences Phase II European Cancer Trial
read more

Edinburgh Molecular Imaging Supports BHF Grant

Edinburgh Molecular Imaging is proud to support the University of Edinburgh team.
The researchers aim to create new chemicals – known as tracers – to illuminate these unstable plaques in patients. The tracers – which contain small amounts of radioactivity – are injected into the bloodstream and stick to the plaques. This allows their detection on an imaging technique known as positron emission tomography (PET) scanning.

See link below:
http://www.ed.ac.uk/medicine-vet-medicine/news-events/latest-news/ps1-8m-bid-to-beat-heart-disease-targets-unseen-ri?utm_campaign=1814884_SCOPE%20CMVM%20staff%20newsletter%20-%20June%202017%20v2&utm_medium=email&utm_source=College%20of%20Medicine%20and%20Veterinary%20Medicine%2C%20The%20University%20of%20Edinburgh&dm_i=2MP1,12WDG,74YGDT,38Y8Y,1

adminEdinburgh Molecular Imaging Supports BHF Grant
read more

EM Imaging in the News

The EM Imaging team hosted Paul Wheelhouse MSP, Minister for Business, Innovation and Energy at our laboratories and offices at Edinburgh Bioquarter. We took the opportunity to explain the value of being based near world leading clinicians who can help us drive our products through clinical trials and to market. We also used this opportunity to campaign for Government and NHS support to drive adoption of our technology within Scotland.

Link to news article http://www.bbc.co.uk/news/uk-scotland-38829002

 

adminEM Imaging in the News
read more

Biotech Showcase

biotech-showcase

Our CEO Ian Wilson will be at the Biotech Showcase on January 9–11 in San Francisco. Contact him through the partnering system to arrange a meeting.

adminBiotech Showcase
read more

EM Imaging Win Best Emerging Medtech Company Award

logo        OBN Awards 2016 – Winners Recognised at Industry Leading Event

At the OBN Awards 2016 dinner in Oxford last night,  Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company Award.

EM Imaging CEO Ian Wilson celebrates wining the Best Emerging Medtech Company Award at OBN 2016.
obn-awards-16-award-eight-best-emerging-medtech-company-winner-edinburgh-molecular-imaging
The Awards, which are in their 8 th year, celebrate the best of UK life sciences – outstanding innovation, fundraisers and achievements – underlining the pre-eminence of the UK sector in the global marketplace.
John Harris, CEO of OBN , said: “We are thrilled with the high quality of nominees this year which made picking just one winner in each category very difficult.   We work hard to keep the awards fresh and have introduced several new categories this year to reflect industry trends. The turn-out and support we’ve received is a true reflection of how buoyant our industry is and I would like to thank our sponsors for helping us make the OBN Awards the success it is today.”
The winners are:
Best Start-up Biotech Company Award Sponsored by Penningtons Manches
Winner: OxStem – for i ts disruptive approach to the field of regenerative medicine
Best Emerging Biotech Company Award Sponsored by Covance
Winner: Mereo BioPharma Group – f or extraordinary progress in the development of products focused on rare and specialty disease areas
Best Established Biotech Company Award Sponsored by Premier Research
Winner: Heptares Therapeutics, for their outstanding acquisitions, impressive product pipeline and industry leading technology
Best Start-up Medtech Company Award Sponsored by JA Kemp
Winner: Precision Ocular, f or making great progress in their strategy to develop novel therapeutics and drug delivery systems to treat retinal disease
Best Emerging Medtech Company Award Sponsored by World Courier
Winner:  Edinburgh Molecular Imaging, for the rapid discovery and clinical development of their optical imaging “SMART Agents”
Best Established Medtech Company Award Sponsored by Arthur J Gallagher
Winner: Oxford Nanopore Technologies, for developing the world’s first and only nanopore DNA sequencer
Best Emerging UK Synthetic Biotech Company Award, Sponsored by SynbiCITE
Winner: Touchlight Genetics, for developing an innovative, in vitro dual enzyme process that produces DNA at commercial scale and quality
Best Implementation of Digital Healthcare Award Sponsored by EY
Winner: Congenica, for its cloud-based technology that supports whole genome analysis from a single DNA test
Best UK Life Sciences Incubator Award Sponsored by James Cowper Kreston
Winner: BioHub at Alderley Park, for running an excellent BioHub that has supported 188 companies and over 600 people resulting in 49 Virtual Companies and 10 Physical Companies
Highest Impact Investor Award Sponsored by N+1 SINGER
Winner: Mercia Technologies, for focusing on the creation, funding and scaling of early stage, innovative technology businesses with high growth, global potential from the UK regions
Best Public-Private Collaboration Award Sponsored by Oxford AHSN
Winner: The Structural Genomics Consortium
Outstanding Achievement Award
Winner: Oxford Nanopore Technologies, for being extremely disruptive in their field and setting an excellent example to the industry
Special Recognition Award
Winner: Neil Woodford CBE, Founding Partner and Head of Investment, Woodford Investment Management

 

adminEM Imaging Win Best Emerging Medtech Company Award
read more

Bio-Europe November 7–9, 2016

bio-europe-logo-01-85c22765389bf3b0976af8657d90a4d1

Ian Wilson and Diane Harbison will be attending Bio-Europe in Cologne. We are interested in speaking to potential investors for our Series B funding round or in opportunities for collaboration using our optical imaging agents. If you are interested in meeting them, please request a meeting through the partnering system or come and hear EM Imaging’s presentation in the Next Generation Session on Wednesday, 9th  November at 10.05

adminBio-Europe November 7–9, 2016
read more

EDINBURGH MOLECULAR IMAGING ARE PART OF A EPSRC FUNDED CONSORTIUM

Edinburgh Molecular Imaging is part of an EPSRC funded consortium, led by Dr Jon Shephard of Heriot-Watt University in collaboration with Professor David Jayne from the University of Leeds to develop a revolutionary new bowel cancer surgery tool that will enable surgeons to carry out operations with far greater precision.

adminEDINBURGH MOLECULAR IMAGING ARE PART OF A EPSRC FUNDED CONSORTIUM
read more